Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Immunon Inc (IMNN) is a clinical-stage biotechnology pioneer developing DNA-based immunotherapies through its proprietary non-viral platform. This page serves as the definitive source for verified company updates, including clinical trial progress, regulatory milestones, and research breakthroughs.
Investors and researchers will find timely updates on key programs like the IMNN-001 ovarian cancer therapy (Phase II completed) and IMNN-101 COVID-19 booster candidate. Our curated news feed covers essential developments including partnership announcements, intellectual property updates, and peer-reviewed study publications.
Content is organized to highlight material events across three core areas: Clinical Trial Advancements, Regulatory Pathway Updates, and Technology Platform Innovations. Each update is vetted for relevance to stakeholders monitoring the company's progress in immuno-oncology and infectious disease applications.
Bookmark this page for structured access to Immunon's official communications, including SEC filings analysis and conference presentation summaries. Check regularly for developments in DNA-based therapeutic approaches that aim to redefine cancer treatment and vaccine development paradigms.
IMUNON (Nasdaq: IMNN) announced a registered direct offering to a single healthcare institutional investor for 1,939,114 shares of common stock (or pre-funded warrants) plus warrants to purchase up to 1,939,114 shares, at a combined purchase price of $3.61 per share and warrant (pre-funded warrant alternative at $3.6099).
The offering is expected to yield approximately $7.0 million gross, with warrants exercisable immediately at $3.482 and expiring five years from issuance; pre-funded warrants have a $0.0001 exercise price and do not expire. The offering will be made under the company’s Form S-3 shelf declared effective May 22, 2024, and is expected to close on or about December 31, 2025.
IMUNON (Nasdaq: IMNN) reported 2025 clinical and operational progress as it advances the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer and prepares toward a potential BLA filing. Key Phase 2 results cited include a 13-month median overall survival (OS) extension (HR 0.70) and an HR of 0.42 in a PARP inhibitor maintenance subgroup. Ongoing MRD translational data show IL-12 induction in macrophages, tumor microenvironment inflammation, lower MRD positivity and improved CRS/PFS signals. Company cites cost reductions in cGMP manufacturing and estimates $30 million to fund OVATION 3 HRD+ subgroup activities. Fast Track and Orphan Drug designations remain in place.
IMUNON (NASDAQ: IMNN) reported third quarter 2025 results and clinical progress on November 13, 2025. The company highlighted a median 13-month overall survival (OS) benefit observed with IMNN-001 in OVATION 2 and translational data showing tumor microenvironment shifts (CD8+ increases, reduced IDO/PD-L1/Treg) in 50-80% and 65-80% of paired samples. IMUNON described expanded Phase 3 OVATION 3 enrollment and an adaptive, event-driven trial design aligned with FDA precedents.
Financially, Q3 net loss was $3.4M (vs $4.8M prior year), operating expenses fell ~30%, and cash was $5.3M, which the company says funds operations into Q1 2026 while it pursues selective financing.
IMUNON (Nasdaq: IMNN) hosted a public webcast on Nov 10, 2025 presenting translational and clinical data for its DNA-mediated immunotherapy IMNN-001.
Speakers included cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 MRD trials, clinicians, statistical experts and IMUNON executives. The event highlighted clinical findings that the company described as showing significant potential for women with advanced ovarian cancer.
A recording and symposium slides are available on IMUNON’s Scientific Presentations page at https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) held an R&D Day on Nov 10, 2025 in New York to present clinical updates for its DNA-mediated immunotherapy IMNN-001 in newly diagnosed advanced ovarian cancer.
Presentations reviewed Phase 2 OVATION 2 and an MRD study, highlighted a reported median 13-month overall survival (OS) benefit for IMNN-001 plus standard-of-care chemotherapy, safety and tolerability data, translational findings on tumor microenvironment remodeling, and progress on the pivotal Phase 3 OVATION 3 trial including activation and enrollment updates. A live webcast and materials were made available on the company scientific presentations page.
IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.
Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.
IMUNON (Nasdaq: IMNN) will host a Third Quarter 2025 Financial Results and Business Update conference call on Thursday, November 13, 2025 at 11:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2025 and provide an update on its Phase 3 clinical development program for IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.
Dial-in numbers are provided for North America and international participants, a live webcast will be available, and the call will be archived for replay through November 27, 2025 with an audio replay accessible for 90 days.
IMUNON (NASDAQ: IMNN) will host an in-person and virtual R&D Day in New York City on November 10, 2025 at the Harvard Club, starting at 8:00 a.m. ET.
The program will provide updates on the pivotal Phase 3 OVATION 3 study and Phase 2 MRD trial for IMNN-001, featuring presentations from ovarian cancer clinicians, Phase 3 investigators, statistical experts, and IMUNON management on safety, translational data, trial design and IMNN-001’s potential role in advanced ovarian cancer. The event includes a live Q&A and networking with speakers.
Registration is available for in-person or virtual attendance via RSVP.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 trial of IMNN-001 at the International Gynecologic Cancer Society Annual Global Meeting, Nov 5-7, 2025 in Cape Town.
IMNN-001 is a DNA-mediated IL-12 plasmid delivered by nanoparticle (TheraPlas platform). The company treated the first patient in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The same TiP poster was also accepted at ESMO 2025.
Poster: "OVATION-3: A randomized phase III trial..." Presenting author: Douglas V. Faller, M.D., Ph.D. Poster number: TP014/#750.
IMUNON (Nasdaq: IMNN) will present new translational data from the Phase 2 OVATION 2 study of IMNN-001 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7, 2025 (Poster #1165, 12:15–1:45 PM ET).
IMNN-001 is a DNA-encoded IL-12 therapy using the TheraPlas® nanoparticle delivery platform. The company says OVATION 2 showed a clinically effective response in newly diagnosed advanced (stage IIIC/IV) epithelial ovarian cancer, including reported benefits in progression-free survival and overall survival, increases in key anti-cancer cytokines, and modulation of immune cell populations (CD8+ T cells, myeloid dendritic cells). IMNN-001 is advancing into the pivotal OVATION 3 Phase 3 trial per plan.
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
